Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1746-1754

  Finch, R ^a   Schurmann D ^a   Collins, O ^a   Kubin, R ^a   McGivern, J ^a   Bobbaers, H ^a   Izquierdo, J L ^a   Nikolaides, P ^a   Ogundare, F ^a   Raz, R ^a   Zuck, P ^a   Hoeffken, G ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CLARITHROMYCIN; CORTICOSTEROID; MACROLIDE; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOEQUIVALENCE; CHLAMYDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIA; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLINES;

EID: 0036096232     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1746-1754.2002     Document Type: Article

References (19)

1. General guidelines for the clinical evaluation of anti-infective drug products
2. Guidelines for the management of community acquired pneumonia in adults admitted to hospital
3. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia
4. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
5. Relation between length of hospital stay and cost of care for patients with community-acquired pneumonia
6. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
7. Community acquired pneumonia: The annual cost to the National Health Service in the UK
8. Advances in antimicrobial therapy of community acquired pneumonia
9. Community acquired pneumonia
10. Incidence of community acquired pneumonia requiring hospitalisation: Results of a population-based active surveillance study in Ohio
11. The crisis in antibiotic resistance
12. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
13. Early switch from intravenous to oral cephalosporin in the treatment of hospitalised patients with community-acquired pneumonia
14. A prospective randomized study of inpatient IV antibiotics for community acquired pneumonia: The optimum duration of therapy
15. The clinical evaluation of antibacterial drugs